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Abstract In 2011, intranasally administered live attenu-
ated influenza vaccine (LAIV) was approved in the EU for
prophylaxis of seasonal influenza in 2–17-year-old chil-
dren. Our objective was to estimate the potential epide-
miological impact and cost-effectiveness of an LAIV-
based extension of the influenza vaccination programme to
healthy children in Germany. An age-structured dynamic
model of influenza transmission was developed and com-
bined with a decision-tree to evaluate different vaccination
strategies in the German health care system. Model inputs
were based on published literature or were derived by
expert consulting using the Delphi technique. Unit costs
were drawn from German sources. Under base-case
assumptions, annual routine vaccination of children aged
2–17 years with LAIV assuming an uptake of 50 % would
prevent, across all ages, 16 million cases of symptomatic
influenza, over 600,000 cases of acute otitis media, nearly
130,000 cases of community-acquired pneumonia, nearly
1.7 million prescriptions of antibiotics and over 165,000
hospitalisations over 10 years. The discounted incremental
cost-effectiveness ratio was €1,228 per quality-adjusted life
year gained from a broad third-party payer perspective
(including reimbursed direct costs and specific transfer
payments), when compared with the current strategy of
vaccinating primarily risk groups with the conventional
trivalent inactivated vaccine. Inclusion of patient co-pay-
ments and indirect costs in terms of productivity losses
resulted in discounted 10-year cost savings of €3.4 billion.
In conclusion, adopting universal influenza immunisation
of healthy children and adolescents would lead to a sub-
stantial reduction in influenza-associated disease at a rea-
sonable cost to the German statutory health insurance
system. On the basis of the epidemiological and health
economic simulation results, a recommendation of
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Universitätsstraße 25, 33615 Bielefeld, Germany
e-mail: oliver.damm@uni-bielefeld.de
M. Eichner
Department of Medical Biometry, University of Tübingen,
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Medical Department, AstraZeneca GmbH, Wedel, Germany
123
Eur J Health Econ (2015) 16:471–488
DOI 10.1007/s10198-014-0586-4
introducing annual routine influenza vaccination of chil-
dren 2–17 years of age might be taken into consideration.
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Background
Annual seasonal influenza epidemics are associated with
considerable health and economic consequences worldwide
[1–3]. Several studies have particularly underlined the
clinical and socioeconomic impact of influenza in children
[4–10]. A recently published review concluded that influ-
enza-related mortality in children is limited, but influenza-
associated paediatric hospitalisation rates are high and
parental work loss is substantial [11].
Influenza is usually a self-limiting condition with sys-
tematic and respiratory symptoms that last up to 7 days in
most people. However, influenza infection can also result
in moderate to severe complications, such as acute otitis
media (AOM), bronchitis, pneumonia and other respiratory
diseases potentially leading to hospitalisation. In rare cases,
influenza can lead to severe non-pulmonary complications,
e.g. cardiac and neurologic complications [12]. Several
management strategies including vaccination and antiviral
treatment are available to cope with seasonal influenza
epidemics. Vaccination is the most effective option for
preventing influenza and related illnesses [13].
Currently, there are two types of seasonal influenza
vaccines licensed for use in Europe: injectable trivalent
inactivated influenza vaccine (TIV) and the nasal spray live
attenuated influenza vaccine (LAIV). While LAIV is
indicated for children and adolescents 2–17 years of age,
non-adjuvanted TIV is licensed for individuals aged
6 months or over. According to two recently published
meta-analyses [14, 15] LAIV showed high levels of pro-
tection against culture-confirmed influenza in children.
Furthermore, LAIV efficacy in children was consistently
found to be higher than efficacy estimates for TIV [14]. In
addition, LAIV was associated with a more sustained
duration of protection than TIV [16–18]. Moreover, a
survey of preferences for influenza vaccine attributes
including efficacy and mode of administration among
children aged 8–12 years found that 79 % of children
favoured the LAIV-like vaccine profile over the TIV
characteristics [19]. As part of the proposed revisions to the
2005 World Health Organization (WHO) position paper on
influenza vaccines, the Strategic Advisory Group of
Experts (SAGE) Influenza Working Group [20] recently
recommended use of LAIV instead of TIV for children
aged 2–5 years because of enhanced levels of protection in
this age group.
In Germany, annual influenza vaccination is mainly
recommended from the age of 60 years and for people with
underlying chronic conditions [21]. Similar influenza im-
munisation policies have been adopted in all other EU
member states. Up to now, only a few countries actually
recommend vaccinating healthy children against seasonal
influenza. However, the number of countries introducing
universal influenza vaccination of children is growing [22,
23]. Current childhood influenza immunisation recom-
mendations use different age ranges for defining the target
group. For example, Canada adopted universal vaccination
for all children aged 6–23 months of age, whereas in the
USA influenza vaccination is recommended for children
and adolescents from 6 months to 18 years of age. Within
Europe, merely nine countries (Austria, Estonia, Finland,
Latvia, Malta, Poland, Romania, Slovakia and Slovenia)
have already established programmes for vaccinating
healthy children against influenza, targeting children of
different age groups from 6 months to 2 years up to
6 months to 18 years [23, 24]. In Germany, only the state of
Saxony recommends vaccination of all children older than
6 months of age against influenza [25]. The UK’s Joint
Committee on Vaccination and Immunisation (JCVI)
recently recommended annual vaccination of children aged
2 to under 17 years against seasonal influenza. Furthermore,
the JCVI pointed out that LAIV should be the vaccine of
choice when implementing the extension of the annual
influenza vaccination programme to healthy children [26].
In recent years, there has been increasing interest in
modelling both the spread of influenza infection and the
economic assessment of potential management strategies.
However, to the best of our knowledge, no previous study
has investigated the epidemiological and health economic
impact of a general influenza vaccination programme
among children with LAIV in the German health care
setting. Thus, the objective of the present modelling study
was to compare the epidemiological and health economic
consequences of an additional LAIV-based routine influ-
enza vaccination programme in children (2–17 years) with
the current practice of primarily vaccinating high-risk
groups with TIV. We applied a dynamic transmission
framework because current evidence suggests that routine
childhood vaccination against influenza could provide
indirect benefits to the community [27–32]. For instance, a
recent US database analysis of hospitalisation records of
older adults and influenza vaccination coverage in children
and older adults revealed that vaccination of young chil-
dren against influenza was associated with a reduction in
the influenza- and pneumonia-associated burden of disease
in the older population [33].
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Materials and methods
Model features
We used Microsoft Excel and Java to develop a mathe-
matical model which simulates the transmission of sea-
sonal influenza as well as different courses of disease and
evaluates the cost-effectiveness of different vaccination
strategies. The economic analysis takes three perspectives:
(1) a societal perspective (including all direct and indirect
costs), (2) a narrow third-party payer perspective (includ-
ing reimbursed direct health care costs only) and (3) a
broad third-party payer perspective (accounting for all
reimbursed direct costs and specific transfer payments). In
the German health care system the third-party payer is
represented by statutory health insurance funds. Cost-
effectiveness results are expressed in terms of incremental
cost-effectiveness ratios (ICERs) and return rates per euro
invested. Cost-effectiveness ratios were calculated as the
incremental cost per additional quality-adjusted life year
(QALY). The approach of using return rates per euro
invested is also known as the concept of benefit–cost ratio
(BCR) which represents the ratio of monetary benefits over
incremental intervention costs and is obtained by dividing
the estimated net savings by the estimated net costs of the
intervention. In our analyses, this ratio is equal to the costs
of influenza infections averted by the childhood immuni-
sation programme divided by the programme costs. The
costs associated with the childhood vaccination programme
include those of the vaccine as well as administration costs
and costs for treating adverse events. Return rates over 1.0
indicate that the childhood vaccination programme yields
overall cost savings to the health care system or the society.
Details of the modelling approach are as follows.
Model design
We used a dynamic modelling approach to simulate the
transmission of influenza and to estimate the impact of
several influenza vaccination strategies on a population
level in Germany [34]. This deterministic and age-struc-
tured compartmental model adapting an extended SEIRS
(susceptible–exposed–infectious–recovered–susceptible)-
type disease transmission model is based on over 4,000
ordinary differential equations. It distinguishes between
influenza A and influenza B infections and roughly
divides the underlying population into seven distinct
groups: individuals who are maternally protected (M),
susceptible (S), exposed in terms of being infected, but
not yet infectious (E), infectious (I), recovered and
immune (R) and subjects who are immune after LAIV
immunisation (VLAIV) or immune following TIV im-
munisation (VTIV).
In addition, we constructed an influenza outcome sub-
tree to account for various respiratory disease patterns and
related health care consumption. The model pathways
include both episodes of uncomplicated but symptomatic
influenza and more complicated courses of disease.
Regarding potential respiratory complications, the model
takes account of AOM and of community-acquired pneu-
monia (CAP). Children who are vaccinated have chances
of developing local or systemic adverse events. For adult
vaccinees, no side effects requiring treatment were con-
sidered. A simplified diagram of the model structure is
provided in Fig. 1.
Population
The simulated population is based on current demographic
data reported by the Federal Statistical Office of Germany
[35]. The results of our population forecast are similar to
the official results of the 12th coordinated population
projection for Germany excluding migration [36]. In the
economic part of the model, the population was divided
into six age and risk groups: children under 2 years of age
(CH 1), children 2–6 years of age (CH 2), children
7–12 years of age (CH 3), adolescents 13–17 years of age
(CH 4), otherwise healthy adults 18–59 years of age
(OHA) and at-risk patients (ARP) comprising individuals
with underlying chronic conditions 18–59 years of age and
the elderly population aged 60 years and over. The pro-
portion of individuals with a chronic condition (such as
chronic respiratory disease, circulatory disorders, endo-
crine disorders, chronic liver and renal disorders, malignant
neoplasms) under the age of 60 was estimated to be 7.6 and
16.6 % for adults 18–44 years of age and adults
45–59 years of age, respectively [37]. Childhood age
groups were not differentiated by risk status, because risk-
stratified vaccination coverage estimates were not available
for children.
Key parameters of the transmission model
We employed the German mixing matrix of the POLY-
MOD study (Improving Public Health Policy in Europe
Through Modelling and Economic Evaluation of Inter-
ventions for the Control of Infectious Diseases) to consider
age-specific contact patterns in our simulations [38]. For
the base-case analysis, we used a seasonally varying basic
reproduction number with an average of 1.6 which lies well
in the range of values (0.9–2.1) estimated by Chowell et al.
[39] regarding seasonal influenza epidemics across three
countries. According to a review of studies describing the
timelines of influenza virus infection [40], we assumed a
1-day period of latent infection (prior to becoming infec-
tious) followed by a 5-day period of viral shedding. We
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further assumed that 30 % of newborns were protected by
maternal antibodies, applying an average duration of
4 months for maternal protection. Following the approach
of Vynnycky et al. [41], the average duration of acquired
immunity after natural infection (modelled by a constant
rate of loss of protection per year) was assumed to be 6 and
12 years for influenza A and B, respectively. More details
on the transmission model are given in a previous publi-
cation [34].
Vaccination programme
The vaccine efficacy data used for LAIV and TIV were
derived from clinical studies and meta-analyses. TIV effi-
cacy among children under 2 years of age, children
2–17 years of age, otherwise healthy adults and ARP was
estimated to be 11, 59, 68 and 58 %, respectively [42–45].
We assumed a nearly complete waning for the TIV-
induced immunity within 1 year. For LAIV among chil-
dren we applied an efficacy of 80 % in the first transmis-
sion season after vaccination based on the mean value of
the estimates of two meta-analyses [45, 46]. A recently
published update of a Cochrane meta-analysis confirmed
this efficacy data [47]. In accordance with an Asian study
[18], we assumed that without revaccination LAIV would
still have a remaining efficacy of 56 % in the second sea-
son. Details on how we modelled waning immunity are
provided in Rose et al. [34]. Adverse events associated
with influenza vaccination were only incorporated for
children who received LAIV. The probabilities of these
adverse events were based on the absolute differences
between LAIV and placebo observed in clinical trials
within 10 days after the first dose [48, 49]. Current TIV-
vaccination rates among children, adults and the elderly in
Germany were obtained from a representative population-
based cross-sectional survey [50, 51]. During a 14-year
run-in phase, the model population was vaccinated with
TIV at current age-specific uptake rates. This initial run-in
period was followed by a subsequent 10-year intervention
phase, where the continuation of TIV use at current vac-
cination coverage levels was compared to the introduction
of an additional routine childhood immunisation pro-
gramme using LAIV. LAIV coverage was assumed to
increase linearly up to 50 % within 3 years, starting with
the age-specific baseline coverage at onset of the childhood
vaccination programme. In the base-case analysis, annual
vaccination takes place in October and November. We
assumed a one-dose vaccination scheme. Table 1 provides
an overview of the vaccination parameters used in the
model.
Clinical events and related health care resource
utilisation patterns
The fraction of symptomatic influenza cases (66.9 %) was
taken from the published literature [40]. Further probabil-
ities of various influenza-associated health outcomes were
obtained from previous studies supplemented by expert
opinion (see Table 2). The model branches consider health
care resource use based on the clinical events that can
occur in subjects being infected and having symptomatic
influenza with or without further complications. All
Uncomplicated
influenza
Symptomatic
disease
Non-symptomatic
disease
Not infected
Influenza and
AOM
Influenza and
CAP
Not vaccinated
Vaccinated
No adverse event
Adverse event
Infected
Output SEIRS model
As above (indicated byt he dotted box)
Fig. 1 Model structure of the
influenza outcome subtree.
AOM acute otitis media,
CAP community-acquired
pneumonia
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individuals who develop symptomatic influenza or influ-
enza-associated respiratory complications are given age-
specific probabilities for self-medicating with over-the-
counter drugs, for consulting a general practitioner, for
receiving prescription medication or for being hospitalised.
Moreover, hospitalised CAP patients face a low probability
of not surviving. All vaccine-related adverse events were
assumed to be medically treated at a rate of 30 %, except
for runny nose, whose treatment probability was set to
10 %. The probability and average amount of related
resource use for each clinical event (e.g. general practi-
tioner visit, prescription medication, hospitalisation) were
obtained from published literature or derived by expert
consulting using the Delphi technique. The expert panel
consisted of six experts specialised in paediatrics, infec-
tious diseases or pulmonology. More details on the Delphi
study are given in the paper on the epidemiological model
[34]. Key parameters of the influenza outcome subtree are
shown in Table 2.
Cost data
As stated in a previous section, model analyses were
performed from three perspectives. The narrow third-party
payer perspective comprises only reimbursed direct
medical costs which include vaccination costs as well as
treatment costs for influenza and its sequelae. In the broad
third-party payer perspective, transfer payments associ-
ated with parental absence from work due to illness of
children up to 12 years were additionally included. These
transfer payments comprise the reimbursement of 70 % of
the work-loss costs of employed parents (Kinderpflegek-
rankengeld, i.e. child care sickness benefits) for up to
10 days per child per year by German statutory sickness
funds. In the societal perspective, patient co-payments for
physician office visits, prescription medication and inpa-
tient services as well as costs of self-medicating with
over-the-counter drugs were included alongside with
reimbursed direct medical costs. Furthermore, indirect
costs associated with production losses due to sick leave
and premature death were considered in the societal
perspective.
Unit costs for health care utilisation were drawn from
German sources only. Drug costs were derived from a
German pharmaceutical database called Lauer-Taxe [61]
using January 2012 information and considering current
manufacturer rebates as well as pharmacy discounts.
Antibiotic therapy was amoxicillin, or in the case of CAP
treatment in ARP, amoxicillin and clavulanic acid com-
bination. Paracetamol (acetaminophen) was used as stan-
dard analgesic and antipyretic therapy. Antitussive therapy
consisted of ambroxol and noscapine. We assumed that
typical self-medication includes use of pain relievers,
nasal spray and cough medicine. The price per dose of
TIV was estimated at €10.64. Vaccine acquisition cost per
dose of LAIV was assumed to be €20.20. This information
was provided by the manufacturer of LAIV (AstraZeneca/
MedImmune). The vaccine administration fee of €6.65
was based on the mean influenza immunisation fee in
Germany. This estimate was the result of a survey of the
17 Associations of Statutory Health Insurance Physicians
(ASHIPs).
Table 1 Vaccination parameters
Parameter Value
(%)
References
Efficacy in the first transmission season after vaccination
TIV among children\2 years 11 Vesikari et al. [42]
TIV among children 2–17 years 59 Jefferson et al. [45]
TIV among OHA 68 Monto et al. [44]
TIV among ARP 58 Jefferson et al. [43]
LAIV among children 80 Jefferson et al. [45];
Rhorer et al. [46]
Probability of LAIV-related adverse events
Runny nose in children 2–6 years 13.5 MedImmune [48]
Runny nose in children
7–17 years
3.9 MedImmune [48]
Headache in children 2–6 years 1.8 MedImmune [48]
Headache in children 7–17 years 6.2 MedImmune [48]
Fever in children 2–6 years 5.5 MedImmune [48]
Fever in children 7–17 years 0.2 MedImmune [48]
Sore throat in children 2–6 years 2.0 MedImmune [48]
Sore throat in children
7–17 years
0.0 MedImmune [48]
Muscle aches in children
2–6 years
2.3 MedImmune [48]
Muscle aches in children
7–17 years
1.9 MedImmune [48]
Vomiting in children 2–6 years 2.5 MedImmune [48]
Vomiting in children 7–17 years 1.5 MedImmune [48]
Yearly baseline vaccination coverage
Children\1 year 0 Assumption
Children 1–2 years 19.2 Blank et al. [50]
Children 3–6 years 22.4 Blank et al. [50]
Children 7–10 years 23.6 Blank et al. [50]
Children 11–17 years 11 Blank et al. [50]
OHA 18–59 years 14.5 Blank et al. [50]
ARP 18–59 years 29.8 Blank et al. [51]
ARP 60–64 years 33.1 Blank et al. [51]
ARP 65–69 years 47.6 Blank et al. [51]
ARP 70 years and over 53.4 Blank et al. [51]
OHA otherwise healthy adults, ARP at-risk patients, TIV trivalent
inactivated influenza vaccine, LAIV live attenuated influenza vaccine
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Unit costs for treatment-related physician visits and
outpatient diagnostic procedures were based on official
tariffs derived from the German physician fee scale called
EBM (Einheitlicher Bewertungsmaßstab) [62] using a
point value of €0.035048 [63]. Hospitalisation costs were
taken from the German DRG (diagnosis-related group)
catalogue [64] considering a base rate of €2,935.78. We
applied the group codes E77G and D62Z for inpatient
treatment of influenza. Hospitalisation of CAP patients was
split up into inpatient stays with and without an intensive
care unit (ICU) admission. CAP-associated hospitalisation
in a general ward was grouped into DRG E77G. Hospi-
talisation of patients with CAP requiring intensive care was
classified as DRGs E40C and A13G.
Indirect costs were calculated according to the friction
cost approach [65] using a friction period of 56 days. This
figure corresponds to the average vacancy period in Ger-
many in 2010 [66]. The average number of work days lost
attributable to influenza, AOM and CAP were obtained
from an administrative database of a German sickness fund
using 2008 data [67], weighted by current age-specific
employment rates. Estimates of parental absence from work
to care for a sick child were taken from a Finnish study [9].
The average cost per work day lost was calculated using
national statistics on income and employment figures and
updated to 2012 values applying the nominal wage growth
rate. We assumed the nominal wage growth rate for 2012 to
be the same as for 2011 (3.3 %). On that basis, mean daily
income per employed person was estimated to be €90.84.
All costs are reported in euro (€) at 2012 price level. All
future costs and benefits were discounted at 3 % according
to German guidelines on economic evaluation in health
care [68]. An overview of the direct cost parameters used
in the model is given in Table 3. Indirect cost inputs are
shown in Table 4.
Health-related quality of life
Influenza-associated symptoms and complications cause
specific reductions in quality of life. Utility values for
influenza and influenza-related complications were based
on published literature and previous modelling studies. As
a result of the lack of specific quality of life estimates for a
German population, we used international data. The quality
of life weight for each day of uncomplicated influenza or
influenza-related AOM was 0.56 [69, 70]. In the study by
Mauskopf et al. [69] the utility weight for influenza illness
was obtained using the quality of well-being scale which
combines a description of the functional status with a
problem symptom complex. The utility value for each day
with CAP was assumed to be 0.52 [70]. This quality of life
weight was derived using data on health states measured by
activity limitation and perceived health. Average durations
of disease states ranging from 4 to 18 days were based on
expert opinion. Because the established side effects of
LAIV are of mild severity, QALY losses due to the
occurrence of adverse events were not considered in this
modelling approach. We assumed a utility of 1 without
symptomatic influenza or associated diseases. Furthermore
premature death due to CAP resulted in a QALY loss based
on the remaining life expectancy.
Time horizon
After a run-in phase of 14 years, using merely current age-
specific TIV-coverage rates, the model followed the entire
German population over additional 10 years in order to
estimate the effects of a supplementary general childhood
influenza vaccination in Germany. The analytic horizon of
10 years was chosen to capture introductory effects of the
new vaccination policy and to account for seasonal varia-
tions in influenza epidemiology.
Sensitivity analyses
We performed a series of sensitivity analyses to evaluate
the robustness of the model. Several deterministic one-way
sensitivity analyses were carried out to test how separate
changes in key variables or assumptions affected the
results. Ranges (given in brackets) are based on published
literature or expert opinion. The varied parameters include
natural history parameters, vaccination parameters and
economic parameters:
• Basic reproduction number (1.3/2.1)
• Duration of viral shedding (3 days/7 days)
• Duration of naturally acquired immunity (±4 years)
• LAIV efficacy (±10 %)
• Halving of childhood vaccination coverage at baseline
• LAIV coverage among children (30 %/70 %)
• Target age range for LAIV (2–6 instead of 2–17 years)
• Use of TIV instead of LAIV
• Halving of the proportion of children seeking outpatient
treatment
• Disease events including symptomatic cases, AOM,
CAP and death of pneumonia (±20 %)
• Vaccine price of LAIV (±20 %)
• Direct treatment costs (±20 %)
• Transfer payments (±20 %)
• Discount rate (0 %/5 %)
• Adjusting the health state utilities for age-specific
baseline values from the general population instead of
assuming a baseline of perfect health [71].
A two-way sensitivity analysis considered different
estimates of two parameters: the coverage rate and the
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maximum target age of the routine childhood immunisation
programme.
Furthermore, a probabilistic sensitivity analysis was
conducted to explore the overall uncertainty by varying all
major model parameters simultaneously using a random
number generator and appropriate distributions. The log-
normal distribution was assigned to cost parameters and
some transmission characteristics of influenza (basic
reproduction number, duration of infectious period and
duration of natural immunity), whereas the beta distribu-
tion was applied to probabilities, utilities and efficacy
estimates.
Model validation
Validation analysis was performed by comparing the
number of outpatient visits predicted by our model using
current vaccination uptake rates with the excess consulta-
tions attributed to influenza estimated on the basis of
German surveillance data [21]. Comparing the average
number of physician consultations per year simulated by
our model with the observed age-specific excess consul-
tations associated with influenza from the 2001–2002 to the
2010–2011 season showed that simulated outpatient visits
lay mostly below the observed rates of excess consulta-
tions. Furthermore, the simulated number of CAP-related
deaths per year was rather low when compared to the
average influenza-associated excess deaths reported for
Germany [72, 73]. Hence, our model tends to underesti-
mate clinical outcomes on seasonal influenza epidemics,
which can be considered a conservative approach.
Results
Epidemiological impact
The number of prevented cases of several clinical out-
comes was used to measure the population-level effects.
Under base-case assumptions, annual routine vaccination
of children with LAIV would prevent, across all ages, an
estimated 16 million cases of symptomatic influenza,
resulting in a reduction of 600,968 cases of AOM and
128,861 cases of CAP over 10 years in Germany if left
undiscounted. Furthermore, an average of 506 pneumonia-
related deaths would be averted per year. Most of the
avoided deaths would be prevented in adults and the
elderly. Because of the decrease in the burden of disease,
an average of 168,239 prescriptions of antibiotics and
16,712 hospitalisations could be prevented annually.
Owing to indirect protection provided by the childhood
vaccination programme, about 60 % of the prevented
hospitalisations would appear in adults and the elderly.T
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Table 5 presents the undiscounted epidemiological results
of the base-case analysis in terms of total cases across all
age groups.
Cost-effectiveness
A summary of the underlying cost analysis is given in
Table 6. The discounted cost-effectiveness results of the
base-case analysis are shown in Table 7. From a narrow
third-party payer perspective, the discounted incremental
cost-effectiveness ratio of a seasonal influenza immunisa-
tion policy including routine childhood vaccination using
LAIV was €2,265 per QALY gained, when compared to
the current strategy of vaccinating primarily risk groups
with TIV. The corresponding return rate per euro invested
was 0.52 from that perspective. From a broad third-party
payer perspective, which takes into account child care
sickness benefits, the incremental cost-effectiveness ratio
was €1,228 per QALY gained and the return rate per euro
invested increased to 0.74. From the societal perspective,
the inclusion of patient co-payments and indirect costs in
terms of production losses resulted in discounted 10-year
cost savings of €3.4 billion. According to this overall cost-
offset, the return rate per euro invested was 5.07 when
taking a societal perspective. In other words, the intro-
duction of routine childhood influenza vaccination would
save €5.07 for each euro invested in the childhood im-
munisation programme.
Sensitivity analyses
We performed a range of one-way sensitivity analyses to
explore the effect of varying key input parameters on
economic results. Taking a broad third-party payer per-
spective into account, the results were sensitive to changes
in the duration of immunity induced by natural influenza
infection, the influenza vaccination coverage rate in chil-
dren and the target age range of the childhood immunisa-
tion programme (parameters are listed in the order of
strength). For instance, reducing the maximum age limit of
target age range from 2–17 to children 2–6 years of age
(while keeping the base-case coverage rate for LAIV at
50 %) increased the return rate to 1.09/€ invested. Cost-
saving results were achieved up to a recommended vacci-
nation age of 7 years when adopting a broad third-party
payer perspective. Sensitivity analyses on the duration of
viral shedding, transfer payments and vaccine price for
LAIV showed moderate to marginal impact on the cost-
effectiveness results. Halving of the childhood vaccination
coverage at baseline led to slightly increased cost-effec-
tiveness ratios (and thus decreased return rates) at an
overall increase in cases prevented. Halving of the pro-
portion of children seeking outpatient treatment also led to
increased cost-effectiveness ratios (such as €1,377 per
QALY gained from a broad third-party payer perspective).
A similar effect was observed when adjusting the health
state utilities for age-specific baseline values (€1,425 per
QALY gained from a broad third-party payer perspective).
Compared to the base-case return rate of 0.74, imple-
menting the routine childhood immunisation programme
using TIV instead of LAIV was associated with a lowered
return rate per euro invested (0.63). In this scenario, the
number of prevented symptomatic influenza cases
decreased (from 1.6 million/year) to an estimated 600,000/
year and the reduction in hospitalisations decreased from
16,712/year in the base-case to 6.444/year. Figure 2 sum-
marises the economic results of various one-way sensitivity
analyses using a tornado chart. Table 8 displays the pre-
vented cases for different outcome measures due to child-
hood vaccination against influenza using LAIV or TIV at
different immunisation uptake levels. Furthermore, we
conducted a two-way sensitivity analysis, where the target
age range of the childhood immunisation programme and
the vaccine uptake of LAIV were varied simultaneously.
The results of this analysis are presented in Table 9.
A probabilistic sensitivity analysis was performed using
Monte Carlo simulation and results were based on 5,000
simulation runs. Figure 3 illustrates the uncertainty sur-
rounding the cost-effectiveness estimate assuming 50 %
LAIV coverage of children 2–17 years of age and adopting a
broad third-party payer perspective. The scatter plot shows
that routine childhood vaccination with LAIV was cost
saving in 17 %of the simulation runs. Figure 4 presents cost-
effectiveness acceptability curves for different LAIV cov-
erage rates adopting either a narrow or a broad third-party
payer perspective. As the graph shows, the introduction of an
influenza immunisation policy including routine childhood
vaccination with LAIV and considering an LAIV uptake of
30 % had a 37 % probability of being cost saving from a
broad third-party payer perspective. Increasing the LAIV
coverage level led to lower probabilities of being cost saving.
However, all scenarios were associated with a greater than
95 % probability of being cost-effective at a willingness to
pay threshold of €20,000 per QALY.
Discussion
This is the first paper to assess the potential cost-effec-
tiveness of a childhood seasonal influenza immunisation
with LAIV in Germany. In this study, a dynamic trans-
mission model was used to estimate 10-year outcomes in
terms of costs and various disease consequences of a rou-
tine childhood influenza vaccination programme in addi-
tion to the current practice of focussing on people with
chronic conditions and the elderly.
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On the basis of our model projections, the introduction
of a routine childhood influenza vaccination programme
assuming 50 % coverage and use of LAIV could lead to a
significant decrease in influenza infections resulting in
decreased morbidity and mortality across all age groups,
reduced hospitalisation rates and antibiotic use as well as
less sickness-related absence from work. Besides direct
effects in children, significant parts of the overall benefits
(up to 84 %) would be caused by indirect effects of the
childhood vaccination programme in people aged 18 and
older.
In Germany, as in most countries, decision makers (Fed-
eral Joint Committee) have not defined thresholds for cost-
effectiveness so far. Nonetheless, considering the commonly
accepted threshold of €50,000 perQALY, the introduction of
a routine childhood vaccination programme appears to be
highly cost-effective from a narrow third-party payer per-
spective (accounting for reimbursed direct health care costs
only) and from a broad third-party payer perspective
(including transfer payments for parental absence from
work). Moreover, our results indicate that the introduction of
a routine childhood influenza vaccination programme using
LAIV could even lead to overall cost savings. Meaningful
cost-offsets were identified when taking a societal perspec-
tive. Hence, cost savings weremainly driven by the inclusion
of indirect costs. Results of univariate sensitivity analyses
suggest that cost savings could also be realised by decreasing
the number of children who receive vaccination, particularly
Table 5 Epidemiological
results of the base-case analysis
AOM acute otitis media,
CAP community-acquired
pneumonia, LAIV live
attenuated influenza vaccine
Undiscounted 10-year
outcomes (overall cases
across all age groups)
Current
policy
Current policy ? LAIV-
based routine childhood
vaccination (2–17 years)
Difference
(total cases
prevented)
Distribution of
avoided cases
by age group
Under
18 years
(%)
18 years
and over
(%)
Infections 58,863,475 34,958,394 23,905,081 38 62
Symptomatic cases 39,379,665 23,387,166 15,992,499 38 62
Cases of AOM 1,145,311 544,343 600,968 83 17
Cases of CAP 282,447 153,586 128,861 57 43
Deaths 13,960 8,902 5,058 16 84
Prescribed antibiotics 4,172,573 2,490,181 1,682,392 38 62
Hospitalisations 406,297 239,178 167,119 42 58
Table 6 Summary of the cost
analysis using base-case
estimates
CP current policy, RCHV
LAIV-based routine childhood
vaccination (2–17 years), TPP
third-party payer, TIV trivalent
inactivated influenza vaccine,
LAIV live attenuated influenza
vaccine
Cost category Discounted 10-year costs (€)
CP CP ? RCHV Difference
Direct medical costs of vaccination against influenza (TPP)
TIV 1,872,816,214.16 1,701,799,776.42 -171,016,437.72
Administration of TIV 1,170,510,133.83 1,063,624,860.26 -106,885,273.57
LAIV 0.00 791,516,964.16 791,516,964.16
Administration of LAIV 0.00 262,916,474.11 262,916,474.11
Treatment of LAIV-associated adverse
events
0.00 57,983,157.76 57,983,157.76
Direct medical costs of treating influenza-related diseases (TPP)
Outpatient medical treatment 239,528,399.93 137,833,556.65 -101,694,843.28
Outpatient pharmaceutical treatment 47,278,534.57 26,436,026.60 -20,842,507.97
Inpatient treatment 759,862,529.73 446,500,962.87 -313,361,566.86
Transfers and indirect costs
Transfers (Kinderpflegekrankengeld) 302,065,027.59 119,571,107.09 -182,493,920.50
Indirect costs in terms of production
losses
10,708,705,718.42 6,997,244,130.30 -3,711,461,588.12
Total costs
Narrow TPP perspective 4,089,995,812.19 4,448,611,778.81 398,615,966.62
Broad TPP perspective 4,392,060,839.78 4,608,182,885.90 216,122,046.12
Societal perspective (including co-
payments and indirect costs)
15,042,784,059.11 11,639,184,713.27 3,403,599,345.84
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by limiting the target age group to children under 8 years of
age when taking a broad third-party payer perspective. In
addition, our probabilistic sensitivity analysis revealed that,
depending on the uptake, routine influenza vaccination of
children was cost saving in up to 37 % of the simulations
performed from the broad third-party payer perspective.
Probabilistic sensitivity analysis also showed that routine
influenza vaccination of children had a very high probability
of being cost-effective at a willingness to pay threshold of
€20,000 per QALY.
A number of previous studies carried out in different
countries have assessed the cost-effectiveness of influenza
vaccination in children (see, for example, overviews by Ni-
chol [74] and Savidan et al. [75]). Compared to the present
analysis, some of these studies provided similar findings.
In a modelling study from Argentina [76], influenza
vaccination of high-risk children aged 6 months to
15 years old was estimated to be cost saving from a soci-
etal perspective. A US-based study [77] demonstrated that
the probability of generating cost savings was highest when
vaccinating high-risk children. Furthermore, indirect costs
were identified as the main drivers of cost savings. Another
US-based study [78] assessing the economic impact of
influenza vaccination in children found that immunisation
of healthy school-aged children was cost saving, primarily
owing to avoided indirect costs. An Italian study [79] also
reported cost-saving results from a societal perspective
when comparing a universal vaccination programme with
an adjuvanted influenza vaccine in children aged
6–60 months to current immunisation practice. A study
Table 7 Economic results of the base-case analysis
Discounted 10-year outcomes Narrow TPP perspective Broad TPP perspective Societal perspective
CP CP ? RCHV CP CP ? RCHV CP CP ? RCHV
Direct costs (€) 4,089,995,812 4,488,611,779 4,089,995,812 4,488,611,779 4,334,078,341 4,641,940,583
Transfers (€) N/A N/A 302,065,028 119,571,107 N/A N/A
Indirect costs (€) N/A N/A N/A N/A 10,708,705,718 6,997,244,130
Total costs (€) 4,089,995,812 4,488,611,779 4,392,060,840 4,608,182,886 15,042,784,059 11,639,184,713
Lost QALYs 449,443 273,483 449,443 273,483 449,443 273,483
ICER (€/QALY) 2,265 1,228 Strategy is dominant
Return rate 0.52 0.74 5.07
CP current policy, RCHV LAIV-based routine childhood vaccination (2–17 years), TPP third-party payer, QALY quality-adjusted life year, ICER
incremental cost-effectiveness ratio, N/A not applicable
0.40 0.60 0.80 1.00 1.20 1.40 1.60
Discount rate (0%/5%)
Vaccine price of LAIV (± 20%)
Transfer payments (± 20%)
LAIV efficacy (± 10%)
Duration of viral shedding (3 days/7 days)
Direct treatment costs (± 20%)
Disease events (± 20%)
Basic reproduction number (1.3/2.1)
LAIV coverage among children (30%/70%)
Target age range (2 to 6 instead of 2 to 17 years)
Duration of naturally acquired immunity (± 4 years)
Return rate per euroinvested
Base case (broad third-party payer perspective)
Fig. 2 Results of one-way sensitivity analyses on key model parameters (the dark bars represent the upper limits whereas the light bars indicate
the lower limits). LAIV live attenuated influenza vaccine
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from Finland [80] evaluated the cost-effectiveness of
influenza vaccination of healthy children 6 months to
13 years of age from a health care provider and a societal
perspective. The authors concluded that a general vacci-
nation of healthy children would be cost saving from both
perspectives considered. In contrast, a Canadian study [81]
analysing the cost-effectiveness of annual influenza vac-
cination for healthy infants and toddlers aged 6–23 months
concluded that influenza immunisation was not cost saving
for this age group from both a third-party payer and a
societal perspective.
To date, only few economic model analyses explicitly
addressed the use of LAIV. One study from the USA [82]
evaluated the cost-effectiveness of LAIV relative to TIV in
children aged 24–59 months assuming a societal perspec-
tive. The authors found that, compared to TIV, vaccinating
children with LAIV was associated with cost savings due
to higher efficacy of LAIV. Another US-based study [83],
assessing the economic impact of childhood influenza
vaccination relative to no vaccination, projected cost-
effectiveness ratios of $15,000 per QALY for LAIV and
$18,000 per QALY for TIV when vaccinating non-high-
risk children aged 2 years; but compared to previously
mentioned studies, the authors did not consider indirect
costs due to parental absence from work associated with
influenza. A study which adopted a societal perspective and
therefore included parental work-loss costs [84] found that
the use of LAIV resulted in net cost savings when the cost
per dose was at or below $36 assuming no parental absence
from work to obtain childhood influenza vaccination.
However, none of these studies have assessed the full
economic impact of routine childhood vaccination against
influenza by use of a dynamic transmission model. As a
consequence, the cost-effectiveness of influenza vaccina-
tion in children has been underestimated. So far, we are
aware of only two studies [85, 86] that applied a trans-
mission model and reported economic effects on
Table 8 Annual averted
disease burden across all age
groups by vaccine type and
coverage rate
AOM acute otitis media,
CAP community-acquired
pneumonia, LAIV live
attenuated influenza vaccine,
TIV trivalent inactivated
influenza vaccine
Outcome measure Average avoided cases per year by vaccine type and coverage rate among
children and adolescents 2–17 years of age (uptake is indicated in brackets)
LAIV
(30 %)
LAIV
(50 %)
LAIV
(70 %)
TIV
(30 %)
TIV
(50 %)
TIV
(70 %)
Influenza infections 1,652,683 2,390,508 2,852,758 375,220 900,924 1,380,496
Symptomatic influenza
cases
1,105,645 1,599,250 1,908,495 251,022 602,718 923,552
Cases of AOM 42,707 60,097 70,226 10,399 25,897 39,049
Cases of CAP 9,050 12,886 15,199 2,118 5,244 7,965
Prescribed antibiotics 115,984 168,239 200,972 25,973 64,131 98,466
Hospitalisations 11,543 16,712 19,933 2,616 6,444 9,875
Deaths 343 506 611 75 184 286
Table 9 Results of a two-way sensitivity analysis varying the target age range of the routine childhood vaccination programme and the vaccine
uptake of LAIV adopting a broad third-party payer perspective
LAIV coverage rate (%) Return rates for different target age ranges (in years) of the routine childhood vaccination programme
2–6 2–7 2–8 2–9 2–10 2–11 2–12 2–13 2–14 2–15 2–16 2–17
30 1.33 1.31 1.28 1.26 1.25 1.20 1.15 1.11 1.08 1.05 1.03 1.01
50 1.09 1.03 0.98 0.94 0.92 0.88 0.84 0.81 0.79 0.77 0.76 0.74a
70 0.92 0.85 0.80 0.76 0.74 0.71 0.67 0.65 0.63 0.62 0.60 0.59
LAIV live attenuated influenza vaccine
a Base case
-20,000
-15,000
-10,000
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Fig. 3 Results of the probabilistic sensitivity analysis (50 % LAIV
coverage; broad third-party payer perspective). QALY quality-
adjusted life year
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vaccinating children against influenza. Unfortunately, the
US-based study by Weycker et al. [86] only specified cost-
offsets due to prevented illnesses but did not incorporate
vaccination costs. In contrast, Giglio et al. [85] reported
results of a full economic evaluation of a paediatric influ-
enza vaccination programme in Argentina, taking into
account direct and indirect benefits of vaccinating children
from 6 months up to 5 years of age. The results of this
recently published study indicate that an influenza vacci-
nation programme targeting preschool-aged children is
cost-effective from a direct cost perspective. In comparison
to our model, the Argentinian simulation study is based on
a different modelling approach which deals with interac-
tions between individuals living in the same or different
households, neighbourhoods and communities and
belonging to various age-related activity groups.
The major strength of our analysis is that, unlike most
previously published economic studies, we used a dynamic
modelling approach to capture not only direct effects but also
population-wide benefits of a universal childhood influenza
immunisation programme. On the other hand, as with any
modelling study, there are potential limitations that should
be considered when interpreting the findings. First, our
model assumed a one-dose vaccination scheme for both
vaccines, even regarding previously unvaccinated individ-
uals. The administration of two initial doses to previously
unvaccinated children would increase vaccination costs and
could alter the cost-effectiveness results. However, the rate
of receipt of two doses is low [87, 88] andLAIV has provided
high efficacy following a single dose in previously unvac-
cinated young children [89]. Second, the data on efficacy of
TIV in children we used in our model is based on the
conventional, non-adjuvanted formulation of the inactivated
vaccine. An adjuvanted version of TIV demonstrated high
vaccine efficacy in children and was found to be more effi-
cacious compared to the non-adjuvanted vaccine [42].
However, the manufacturer of the adjuvanted vaccine
withdrew its application for paediatric-use marketing au-
thorisation in Europe. Third, as a result of a lack of detailed
data, assumptions about the immunity to natural influenza
infection rely solely on a previous modelling study. Fur-
thermore, missing age-specific data on natural history esti-
mates and resource utilisation patterns were derived from
expert opinion. Fourth, simulated influenza-related compli-
cations were limited to AOM and CAP. However, influenza
can cause other severe as well as costly illnesses and even
life-threatening complications. As a consequence, ourmodel
may underestimate the real impact of a routine childhood
vaccination. Fifth, comorbidities were not considered when
calculating hospitalisation costs, thus resulting in an under-
estimation of these cost components. Finally, we could not
conduct extensive validation analyses as a result of a lack of
data on different influenza-associated events in Germany.
However, the results of validation analysis using excess
consultations suggest that the model projects quite realistic
but conservative scenarios.
Conclusions
In deciding whether to reimburse new health care inter-
ventions, decision makers increasingly consider both the
health effects and the potential economic implications of
the different programmes under consideration. Thus, we
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conducted a cost-effectiveness analysis of a general influ-
enza vaccination programme in children and adolescents
using LAIV in Germany.
Taking cost-effectiveness ratios of €2,265 and €1,228
per QALY gained into account, annual routine vaccination
of children 2–17 years of age with LAIV appears a highly
cost-effective option from a narrow and a broad third-party
payer perspective, respectively. When adopting a societal
perspective, routine vaccination of children and adoles-
cents against seasonal influenza with LAIV appears a cost-
saving strategy.
Compared to the current vaccination policy, the intro-
duction of a universal childhood vaccination programme
using LAIV can substantially increase benefits and reduce
the influenza-associated burden of disease in Germany.
Furthermore, our model results suggest that routine influ-
enza vaccination targeting children and adolescents offers
not only advantages for the target group, but provides
significant health benefits to the whole population.
In summary, adopting universal influenza immunisation
of healthy children and adolescents provides good value for
money for the German statutory health insurance system.
On the basis of the epidemiological and health economic
simulation results, the implementation of annual routine
influenza vaccination of children 2–17 years of age should
be taken into consideration. Taking into account the effi-
cacy profile, the convenient and painless route of admin-
istration as well as the results of our model analysis, live
virus vaccines might be an important part of a general
influenza vaccination programme for children from the age
of two upwards.
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